{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T06:18:58Z","timestamp":1783491538898,"version":"3.55.0"},"reference-count":54,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T00:00:00Z","timestamp":1783468800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100010256","name":"Guangzhou Municipal Science and Technology Project","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100010256","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Nutr."],"abstract":"<jats:sec>\n                    <jats:title>Background and aim<\/jats:title>\n                    <jats:p>Gut-liver axis dysfunction drives metabolic associated fatty liver disease (MAFLD), but effective therapeutic strategies remain limited. Bletilla striata oligosaccharides (BSO) have immunomodulatory potential, yet their role in MAFLD via the gut-liver axis is unclear. This study aimed to investigate whether and how BSO ameliorates MAFLD by modulating gut microbiota, intestinal barrier function, and hepatic inflammation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>MAFLD was induced in mice by 8-week high-fat diet followed by 12-week BSO (150, 300, 600 mg\/kg) or metformin treatment via oral gavage. Compared with the MAFLD model, high-dose BSO reduced body weight gain, lowered fasting glucose, and decreased hepatic triglycerides. BSO also attenuated liver injury, hepatic steatosis, inflammation. Mechanistically, BSO restored gut barrier integrity, upregulated colonic tight junction proteins, activated colonic LXR\u03b1\/ABCA1 signaling, while suppressing the hepatic TLR4\/NF-\u03baB pathway. BSO remodeled gut microbiota, enriching beneficial Lachnospiraceae and Oscillospiraceae, and modulated hepatic metabolites, as shown by decreased confertifoline along with increased D-myo-inositol-4-phosphate. Additionally, BSO activated the intestinal FXR\/FGF15 axis and ameliorated bile acid metabolism disorders, evidenced by reduced tauro-\u03c9-muricholic acid and cholic acid.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This study provides systematic evidence that BSO alleviates MAFLD through a multi-target gut-liver axis mechanism involving gut microbiota remodeling, barrier restoration, activation of LXR\u03b1\/ABCA1 and FXR\/FGF15 signaling, and subsequent suppression of hepatic TLR4\/NF-\u03baB-driven inflammation. Compared to previous approaches, BSO offers a favorable safety profile with combined regulatory effects. These findings support BSO as a promising candidate for MAFLD treatment, with potential applications as a dietary supplement or prebiotic agent.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fnut.2026.1852189","type":"journal-article","created":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T05:58:18Z","timestamp":1783490298000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Bletilla striata oligosaccharides alleviate high-fat diet-induced metabolic associated fatty liver in mice through modulation of gut microbiota and host metabolism"],"prefix":"10.3389","volume":"13","author":[{"given":"Kaiwen","family":"Lei","sequence":"first","affiliation":[{"name":"Guangdong Engineering Research Center of Natural Products and New Drugs, Guangdong Provincial University Engineering Technology Research Center of Natural Products and Drugs, Guangdong Pharmaceutical University","place":["Guangzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Li","sequence":"additional","affiliation":[{"name":"Guangdong Provincial Key Laboratory of Pharmaceutical Bioactive Substances and School of Basic Medical Sciences, Guangdong Pharmaceutical University","place":["Guangzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kunhua","family":"Wei","sequence":"additional","affiliation":[{"name":"Key Laboratory of State Administration of Traditional Chinese Medicine for Production and Development of Cantonese Medicinal Materials, Guangzhou Comprehensive Experimental Station of National Industrial Technology System for Chinese Materia Medica, Guangdong Engineering Research Center of Good Agricultural Practice and Comprehensive Development for Cantonese Medicinal Materials, School of Chinese Materia Medica, Guangdong Pharmaceutical University","place":["Guangzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Bai","sequence":"additional","affiliation":[{"name":"Health Sciences Academy, Guangzhou Nanyang Polytechnic College","place":["Guangzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianwen","family":"Mao","sequence":"additional","affiliation":[{"name":"Guangdong Provincial Key Laboratory of Pharmaceutical Bioactive Substances and School of Basic Medical Sciences, Guangdong Pharmaceutical University","place":["Guangzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhengquan","family":"Su","sequence":"additional","affiliation":[{"name":"Guangdong Engineering Research Center of Natural Products and New Drugs, Guangdong Provincial University Engineering Technology Research Center of Natural Products and Drugs, Guangdong Pharmaceutical University","place":["Guangzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,7,8]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1999","DOI":"10.1053\/j.gastro.2019.11.312","article-title":"MAFLD: a consensus-driven proposed nomenclature for metabolic associated fatty liver disease.","volume":"158","author":"Eslam","year":"2020","journal-title":"Gastroenterology."},{"key":"B2","doi-asserted-by":"publisher","first-page":"1797","DOI":"10.1097\/HEP.0000000000000323","article-title":"AASLD practice guidance on the clinical assessment and management of nonalcoholic fatty liver disease.","volume":"77","author":"Rinella","year":"2023","journal-title":"Hepatology."},{"key":"B3","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1007\/s12072-024-10774-3","article-title":"The asian pacific association for the study of the liver clinical practice guidelines for the diagnosis and management of metabolic dysfunction-associated fatty liver disease.","volume":"19","author":"Eslam","year":"2025","journal-title":"Hepatol Int."},{"key":"B4","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1016\/j.tem.2024.02.007","article-title":"Current status and future trends of the global burden of MASLD.","volume":"35","author":"Miao","year":"2024","journal-title":"Trends Endocrinol Metab."},{"key":"B5","doi-asserted-by":"publisher","first-page":"1699508","DOI":"10.3389\/fgstr.2025.1699508","article-title":"The global landscape of lean metabolic dysfunction-associated steatotic liver disease: insight from asia and the west.","volume":"4","author":"Purnomo","year":"2025","journal-title":"Front Gastroenterol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1002\/hep.32499","article-title":"Are there outcome differences between NAFLD and metabolic-associated fatty liver disease?","volume":"76","author":"Younossi","year":"2022","journal-title":"Hepatology."},{"key":"B7","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1136\/gutjnl-2020-323082","article-title":"Non-alcoholic fatty liver disease and risk of incident chronic kidney disease: an updated meta-analysis.","volume":"71","author":"Mantovani","year":"2022","journal-title":"Gut."},{"key":"B8","doi-asserted-by":"publisher","first-page":"1526","DOI":"10.1111\/liv.15930","article-title":"The first MASH drug therapy on the horizon: Current perspectives of resmetirom.","volume":"44","author":"Petta","year":"2024","journal-title":"Liver Int."},{"key":"B9","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.1016\/j.metabol.2015.12.012","article-title":"The multiple-hit pathogenesis of Non-Alcoholic Fatty Liver Disease (NAFLD).","volume":"65","author":"Buzzetti","year":"2016","journal-title":"Metabolism."},{"key":"B10","doi-asserted-by":"publisher","first-page":"S47","DOI":"10.1016\/j.jhep.2014.12.012","article-title":"NAFLD: a multisystem disease.","volume":"62","author":"Byrne","year":"2015","journal-title":"J Hepatol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1038\/s41579-023-00904-3","article-title":"The gut\u2013liver axis and gut microbiota in health and liver disease.","volume":"21","author":"Hsu","year":"2023","journal-title":"Nat Rev Microbiol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"179","DOI":"10.15586\/qas.v17i4.1544","article-title":"Extraction, characterization, and impact of tartary buckwheat husk dietary fiber on metabolic functions and gut microbiota composition in obese mice.","volume":"17","author":"Lin","year":"2025","journal-title":"Qual Assur Saf Crops Foods."},{"key":"B13","doi-asserted-by":"publisher","first-page":"1635","DOI":"10.1126\/science.1110591","article-title":"Diversity of the human intestinal microbial flora.","volume":"308","author":"Eckburg","year":"2005","journal-title":"Science."},{"key":"B14","doi-asserted-by":"publisher","first-page":"120197","DOI":"10.1016\/j.carbpol.2022.120197","article-title":"\u03b1-D-1,3-glucan from radix puerariae thomsonii improves NAFLD by regulating the intestinal flora and metabolites.","volume":"299","author":"Li","year":"2023","journal-title":"Carbohydrate Polymers."},{"key":"B15","doi-asserted-by":"publisher","first-page":"1635638","DOI":"10.3389\/fcimb.2025.1635638","article-title":"Gut microbiota and metabolomics in metabolic dysfunction-associated fatty liver disease: interaction, mechanism, and therapeutic value.","volume":"15","author":"Wang","year":"2025","journal-title":"Front Cell Infect Microbiol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"1216","DOI":"10.1016\/j.jhep.2019.08.005","article-title":"Microbiota-driven gut vascular barrier disruption is a prerequisite for non-alcoholic steatohepatitis development.","volume":"71","author":"Mouries","year":"2019","journal-title":"J Hepatol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1146\/annurev-immunol-051116-052415","article-title":"Immune responses in the liver.","volume":"36","author":"Kubes","year":"2018","journal-title":"Annu Rev Immunol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"e12173","DOI":"10.1002\/smll.202512173","article-title":"Exposure to grilled lamb-borne carbon quantum dots induces intrahepatic cholestasis by activating the intestinal microbial-derived lipopolysaccharide-TLR4 pathway.","volume":"22","author":"Xu","year":"2026","journal-title":"Small."},{"key":"B19","doi-asserted-by":"publisher","first-page":"17947","DOI":"10.1074\/jbc.M112.442699","article-title":"High density lipoprotein protects against polymicrobe-induced sepsis in mice.","volume":"288","author":"Guo","year":"2013","journal-title":"J Biol Chem."},{"key":"B20","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1038\/nrm3312","article-title":"Transcriptional integration of metabolism by the nuclear sterol-activated receptors LXR and FXR.","volume":"13","author":"Calkin","year":"2012","journal-title":"Nat Rev Mol Cell Biol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1038\/s41574-018-0037-x","article-title":"Liver X receptors in lipid signalling and membrane homeostasis.","volume":"14","author":"Wang","year":"2018","journal-title":"Nat Rev Endocrinol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"142275","DOI":"10.1016\/j.ijbiomac.2025.142275","article-title":"Mechanism of liver x receptor alpha in intestine, liver and adipose tissues in metabolic associated fatty liver disease.","volume":"307","author":"Lei","year":"2025","journal-title":"Intern J Biol Macromol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"1655873","DOI":"10.3389\/fphar.2025.1655873","article-title":"TLR4 modulates simvastatin\u2019s impact on HDL cholesterol and glycemic control.","volume":"16","author":"Tian","year":"2026","journal-title":"Front Pharmacol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"116519","DOI":"10.1016\/j.biopha.2024.116519","article-title":"The effects of atractylodes macrocephala extract BZEP self-microemulsion based on gut\u2013liver axis HDL\/LPS signaling pathway to ameliorate metabolic dysfunction-associated fatty liver disease in rats.","volume":"175","author":"Li","year":"2024","journal-title":"Biomed Pharmacotherapy."},{"key":"B25","doi-asserted-by":"publisher","first-page":"eabe6729","DOI":"10.1126\/science.abe6729","article-title":"Enterically derived high-density lipoprotein restrains liver injury through the portal vein.","volume":"373","author":"Han","year":"2021","journal-title":"Science."},{"key":"B26","doi-asserted-by":"publisher","first-page":"2717","DOI":"10.1016\/j.cell.2024.03.034","article-title":"Gut symbionts alleviate MASH through a secondary bile acid biosynthetic pathway.","volume":"187","author":"Nie","year":"2024","journal-title":"Cell."},{"key":"B27","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/j.jhep.2024.09.032","article-title":"Bile acid metabolism and signalling in liver disease.","volume":"82","author":"Fuchs","year":"2025","journal-title":"J Hepatol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"1881","DOI":"10.1136\/gutjnl-2017-314307","article-title":"Suppressed hepatic bile acid signalling despite elevated production of primary and secondary bile acids in NAFLD.","volume":"67","author":"Jiao","year":"2018","journal-title":"Gut."},{"key":"B29","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1080\/13543784.2020.1763302","article-title":"Bile acid modulators for the treatment of nonalcoholic steatohepatitis (NASH).","volume":"29","author":"Fiorucci","year":"2020","journal-title":"Exp Opin Invest Drugs."},{"key":"B30","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1159\/000493297","article-title":"Ganoderma lucidum polysaccharide peptide alleviates hepatoteatosis via modulating bile acid metabolism dependent on FXR-SHP\/FGF.","volume":"49","author":"Zhong","year":"2018","journal-title":"Cell Physiol Biochem."},{"key":"B31","doi-asserted-by":"publisher","first-page":"165","DOI":"10.15586\/qas.v17i2.1534","article-title":"The role of fiber in gut health and chronic diseases: a comprehensive review.","volume":"17","author":"Maqsood","year":"2025","journal-title":"Qual Assur Saf Crops Foods."},{"key":"B32","doi-asserted-by":"publisher","first-page":"125407","DOI":"10.1016\/j.ijbiomac.2023.125407","article-title":"Extraction, structural-activity relationships, bioactivities, and application prospects of bletilla striata polysaccharides as ingredients for functional products: a review.","volume":"245","author":"Zhu","year":"2023","journal-title":"Intern J Biol Macromol."},{"key":"B33","doi-asserted-by":"publisher","first-page":"1688676","DOI":"10.3389\/fphar.2025.1688676","article-title":"Recent advances in bletilla striata polysaccharide research: extraction methodologies, structural elucidation, pharmacological mechanisms, structure\u2013activity relationships, and therapeutic delivery applications.","volume":"16","author":"Wang","year":"2025","journal-title":"Front Pharmacol."},{"key":"B34","doi-asserted-by":"publisher","first-page":"2653","DOI":"10.3390\/foods14152653","article-title":"Dietary interventions with bletilla striata polysaccharides and\/or composite polysaccharides remodel liver lipid profiles and ameliorate gut metabolic disturbances in high-fat diet-induced obese mice.","volume":"14","author":"Zhang","year":"2025","journal-title":"Foods."},{"key":"B35","doi-asserted-by":"publisher","first-page":"104942","DOI":"10.1016\/j.phrs.2020.104942","article-title":"Bletilla striata oligosaccharides improve metabolic syndrome through modulation of gut microbiota and intestinal metabolites in high fat diet-fed mice.","volume":"159","author":"Hu","year":"2020","journal-title":"Pharmacol Res."},{"key":"B36","doi-asserted-by":"publisher","first-page":"4757","DOI":"10.1039\/d1fo03899k","article-title":"Structural characterization and preventive effect on non-alcoholic fatty liver disease of oligosaccharides from bletilla striata.","volume":"13","author":"Hu","year":"2022","journal-title":"Food Funct."},{"key":"B37","doi-asserted-by":"publisher","first-page":"867525","DOI":"10.3389\/fphar.2022.867525","article-title":"Bletilla striata oligosaccharides improve ulcerative colitis by regulating gut microbiota and intestinal metabolites in dextran sulfate sodium-induced mice.","volume":"13","author":"Zhu","year":"2022","journal-title":"Front Pharmacol."},{"key":"B38","doi-asserted-by":"publisher","first-page":"10459","DOI":"10.1039\/d3fo03745b","article-title":"Ameliorating the effect and mechanism of chitosan oligosaccharide on nonalcoholic fatty liver disease in mice.","volume":"14","author":"Zhang","year":"2023","journal-title":"Food Funct."},{"key":"B39","doi-asserted-by":"publisher","first-page":"155919","DOI":"10.1016\/j.phymed.2024.155919","article-title":"Yellow tea polysaccharides protect against non-alcoholic fatty liver disease via regulation of gut microbiota and bile acid metabolism in mice.","volume":"133","author":"Huang","year":"2024","journal-title":"Phytomedicine."},{"key":"B40","doi-asserted-by":"publisher","first-page":"43728","DOI":"10.1038\/srep43728","article-title":"HDL glycoprotein composition and site-specific glycosylation differentiates between clinical groups and affects IL-6 secretion in Lipopolysaccharide-stimulated monocytes.","volume":"7","author":"Krishnan","year":"2017","journal-title":"Sci Rep."},{"key":"B41","doi-asserted-by":"publisher","first-page":"100858","DOI":"10.1016\/j.jlr.2025.100858","article-title":"High-density lipoprotein attenuates lipopolysaccharide-induced IL-1\u03b2 activation via scavenger receptor class B type 1.","volume":"66","author":"Deng","year":"2025","journal-title":"J Lipid Res."},{"key":"B42","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1016\/j.jcis.2025.02.131","article-title":"The interaction of human serum components with model membranes containing phospholipids and lipopolysaccharides.","volume":"688","author":"Paracini","year":"2025","journal-title":"J Colloid Interface Sci."},{"key":"B43","doi-asserted-by":"publisher","first-page":"1496","DOI":"10.1177\/2050640618804444","article-title":"Fecal SCFAs and SCFA-producing bacteria in gut microbiome of human NAFLD as a putative link to systemic T-cell activation and advanced disease.","volume":"6","author":"Rau","year":"2018","journal-title":"UEG J."},{"key":"B44","doi-asserted-by":"publisher","first-page":"432-445.e7","DOI":"10.1016\/j.immuni.2018.12.018","article-title":"The short chain fatty acid butyrate imprints an antimicrobial program in macrophages.","volume":"50","author":"Schulthess","year":"2019","journal-title":"Immunity."},{"key":"B45","doi-asserted-by":"publisher","first-page":"3640","DOI":"10.3390\/ijms25073640","article-title":"The reduced gut lachnospira species is linked to liver enzyme elevation and insulin resistance in pediatric fatty liver disease.","volume":"25","author":"Tsai","year":"2024","journal-title":"IJMS."},{"key":"B46","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1016\/j.tim.2016.02.015","article-title":"Oscillospira?: a central, enigmatic component of the human gut microbiota.","volume":"24","author":"Konikoff","year":"2016","journal-title":"Trends Microbiol."},{"key":"B47","doi-asserted-by":"publisher","first-page":"15272","DOI":"10.3390\/ijms242015272","article-title":"Gut microbiota patterns in patients with non-alcoholic fatty liver disease: a comprehensive assessment using three analysis methods.","volume":"24","author":"Korobeinikova","year":"2023","journal-title":"IJMS."},{"key":"B48","doi-asserted-by":"publisher","first-page":"739","DOI":"10.3390\/biom12060739","article-title":"Myristic acid supplementation aggravates high fat diet-induced adipose inflammation and systemic insulin resistance in mice.","volume":"12","author":"Saraswathi","year":"2022","journal-title":"Biomolecules."},{"key":"B49","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1097\/SHK.0b013e31819c3414","article-title":"The novel inosine analogue ino-2002 exerts an anti-inflammatory effect in a murine model of acute lung injury.","volume":"32","author":"Mabley","year":"2009","journal-title":"Shock."},{"key":"B50","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.jnutbio.2013.09.004","article-title":"Nicotinamide improves glucose metabolism and affects the hepatic NAD-sirtuin pathway in a rodent model of obesity and type 2 diabetes.","volume":"25","author":"Yang","year":"2014","journal-title":"J Nutritional Biochem."},{"key":"B51","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1172\/JCI107233","article-title":"Triketocholanoic (dehydrocholic) acid. hepatic metabolism and effect on bile flow and biliary lipid secretion in man.","volume":"52","author":"Soloway","year":"1973","journal-title":"J Clin Invest."},{"key":"B52","doi-asserted-by":"publisher","first-page":"6469","DOI":"10.2147\/DDDT.S530823","article-title":"DHLCA alleviates diabetic kidney disease via TGR5\/FXR activation and gut microbiota remodeling.","volume":"19","author":"Zhou","year":"2025","journal-title":"DDDT."},{"key":"B53","doi-asserted-by":"publisher","first-page":"2005","DOI":"10.3390\/molecules28052005","article-title":"Taurocholic acid and glycocholic acid inhibit inflammation and activate farnesoid X receptor expression in LPS-stimulated zebrafish and macrophages.","volume":"28","author":"Ge","year":"2023","journal-title":"Molecules."},{"key":"B54","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.jceh.2021.08.017","article-title":"Shalimar. A current understanding of bile acids in chronic liver disease.","volume":"12","author":"Farooqui","year":"2022","journal-title":"J Clin Exp Hepatol."}],"container-title":["Frontiers in Nutrition"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fnut.2026.1852189\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T05:58:19Z","timestamp":1783490299000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fnut.2026.1852189\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,8]]},"references-count":54,"alternative-id":["10.3389\/fnut.2026.1852189"],"URL":"https:\/\/doi.org\/10.3389\/fnut.2026.1852189","relation":{},"ISSN":["2296-861X"],"issn-type":[{"value":"2296-861X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,8]]},"article-number":"1852189"}}